Related Experiment Video
Updated: Jan 22, 2026

Portable Thermographic Screening for Detection of Acute Wallenberg's Syndrome
Published on: September 19, 2019
Biomarkers for acute cardiorenal syndrome
Pei-Chun Fan1,2, Chih-Hsiang Chang1,2, Yung-Chang Chen3
1Department of Nephrology, Kidney Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Insights
Emerging biomarkers offer improved early detection and assessment for cardiorenal syndrome type I (CRS I), a condition involving heart and kidney dysfunction. These markers aid in differential diagnosis, severity evaluation, and prognosis, enhancing patient management for CRS I.
Area of Science:
- Cardiology
- Nephrology
- Biomarker Research
Background:
- Cardiorenal syndromes involve heart and kidney dysfunction.
- Cardiorenal syndrome type I (CRS I) is acute kidney injury from acute cardiac dysfunction.
- Traditional markers like serum creatinine have limitations in diagnosing CRS I.
Purpose of the Study:
- Review emerging biomarkers for CRS I.
- Evaluate their potential for early detection and diagnosis.
- Assess their role in disease severity and prognosis.
Main Methods:
- Literature review of emerging biomarkers.
- Analysis of biomarker utility in CRS I.
- Comparison with traditional diagnostic markers.
Main Results:
- Several biomarkers show promise for CRS I.
- These include BNP, sST2, angiopoietin, and others.
- Biomarkers may improve early detection and prognosis.
Conclusions:
- Emerging biomarkers can enhance CRS I diagnosis and management.
- They offer advantages over traditional markers for CRS I.
- Improved patient outcomes are anticipated with biomarker use.
Abstract:
Cardiorenal syndromes are disorders of the heart and kidneys whereby dysfunction in one organ may lead to dysfunction in the other organ. Cardiorenal syndrome type I (CRS I) is defined as acute kidney injury caused by acute cardiac dysfunction such as acute decompensated heart failure and acute coronary syndrome. Traditional markers like serum creatinine may delay the diagnosis of acute kidney injury and provide limited information regarding the underlying pathophysiology in the setting of CRS I. Herein, we briefly review some emerging biomarkers, including brain natriuretic peptide, soluble ST2, angiopoietin, soluble thrombomodulin, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C, interleukin-18 and calprotectin. These biomarkers may help early detecting, differential diagnosis, assessing disease severity and prognosis in patients with CRS I, therefore improve patient management and outcomes.
Related Concept Videos
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction

